Details of the Drug
General Information of Drug (ID: DMFNH7L)
Drug Name |
Pentobarbital
|
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
|
||||||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||||||
Therapeutic Class |
Hypnotics and Sedatives
|
||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 226.27 | |||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Brain ischaemia | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 8B1Z | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Pentobarbital
Coadministration of a Drug Treating the Disease Different from Pentobarbital (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Pentobarbital FDA Label | ||||
---|---|---|---|---|---|
2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5480). | ||||
3 | Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches | ||||
4 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
5 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
6 | DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. | ||||
7 | CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5. | ||||
8 | [Development of oral vaccine carrying GCPII gene and its role in reducing the dosage of pentobarbital in rat: a primitive research]. Zhonghua Yi Xue Za Zhi. 2004 Jul 17;84(14):1152-6. | ||||
9 | Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19. | ||||
10 | Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. doi: 10.1007/s00210-001-0490-1. Epub 2001 Nov 8. | ||||
11 | GLUT1-deficiency: barbiturates potentiate haploinsufficiency in vitro. Pediatr Res. 1999 Dec;46(6):677-83. doi: 10.1203/00006450-199912000-00006. | ||||
12 | The reduction of tumor necrosis factor-alpha release and tissue damage by pentobarbital in the experimental endotoxemia model. Shock. 2007 Sep;28(3):309-16. doi: 10.1097/SHK.0b013e31803dd04d. | ||||
13 | Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ. | ||||
14 | Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA. | ||||
15 | Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD. | ||||
16 | Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY. | ||||
17 | Cerner Multum, Inc. "Australian Product Information.". | ||||
18 | Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179] | ||||
19 | Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261] | ||||
20 | Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL. | ||||
21 | Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA. | ||||
22 | Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ. | ||||
23 | Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY. | ||||
24 | Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276] | ||||
25 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
26 | Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ. | ||||
27 | Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984] | ||||
28 | Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ. | ||||
29 | Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153] | ||||
30 | Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY. | ||||
31 | Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA. | ||||
32 | Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380] | ||||
33 | Ambrose PJ "Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate." Clin Pharmacokinet 9 (1984): 222-38. [PMID: 6375931] | ||||
34 | Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN. | ||||
35 | Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI. | ||||
36 | Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674] | ||||
37 | Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA. | ||||
38 | Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
39 | Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249] | ||||
40 | Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ. | ||||
41 | Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106] | ||||
42 | Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
43 | Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243] | ||||
44 | Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899] | ||||
45 | Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA. | ||||
46 | Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340] | ||||
47 | Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
48 | US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.". | ||||
49 | Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421] | ||||
50 | Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002] | ||||
51 | Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ. | ||||
52 | Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045] | ||||
53 | Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456] | ||||
54 | US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.". | ||||
55 | Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383] | ||||
56 | Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA. | ||||
57 | Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ. | ||||
58 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
59 | Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537] | ||||
60 | Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA. | ||||
61 | Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7. [PMID: 2198298] | ||||
62 | Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT. | ||||
63 | Product Information. Paxil (paroxetine). GlaxoSmithKline, Research Triangle Park, NC. | ||||
64 | Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL. | ||||
65 | Busfield D, Child KJ, Atkinson RM, Tomich EG "An effect of phenobarbitone on blood-levels of griseofulvin in man." Lancet 2 (1963): 1042-3. [PMID: 14062729] | ||||
66 | Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137] | ||||
67 | Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ. | ||||
68 | Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925] | ||||
69 | Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354] | ||||
70 | Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497] | ||||
71 | Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342] | ||||
72 | Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207] | ||||
73 | Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
74 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
75 | Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC. | ||||
76 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
77 | Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
78 | Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA. | ||||
79 | Somogyi A, Thielscher S, Gugler R "Influence of phenobarbital treatment on cimetidine kinetics." Eur J Clin Pharmacol 19 (1981): 343-7. [PMID: 7238562] | ||||
80 | Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA. | ||||
81 | Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493] | ||||
82 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
83 | Richter E, Breimer DD, Zilly W "Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents." Eur J Clin Pharmacol 17 (1980): 197-202. [PMID: 7363932] | ||||
84 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
85 | Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416] | ||||
86 | Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416] | ||||
87 | Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC. | ||||
88 | Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870] | ||||
89 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
90 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
91 | Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mcwilliams EJ, Mccrea JB "Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite e-3174." Clin Pharmacol Ther 59 (1996): 268-74. [PMID: 8653989] | ||||
92 | Rutledge DR, Pieper JA, Mirvis DM "Effects of chronic phenobarbital on verapamil dispostion in humans." J Pharmacol Exp Ther 246 (1988): 7-13. [PMID: 3392664] | ||||
93 | Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427] | ||||
94 | Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492] | ||||
95 | Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
96 | Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
97 | Cerner Multum, Inc. "Canadian Product Information.". | ||||
98 | Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
99 | Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239] | ||||
100 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
101 | Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
102 | Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
103 | Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004] | ||||
104 | Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ. | ||||
105 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
106 | Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL. | ||||
107 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
108 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
109 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
110 | Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA. | ||||
111 | Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
112 | Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO. | ||||
113 | Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA. | ||||
114 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
115 | Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN. | ||||
116 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
117 | Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
118 | Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ. | ||||
119 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
120 | Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE. | ||||
121 | Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865] | ||||
122 | Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA. | ||||
123 | Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA. | ||||
124 | James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294] | ||||
125 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
126 | Paolini A, D'Incalci M "Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine." Cancer Treat Rep 70 (1986): 513-6. [PMID: 3084083] | ||||
127 | Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251] | ||||
128 | Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200] | ||||
129 | Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J "Paracetamol as a test drug to determine glucuronide formation in man: effects of inducers and of smoking." Eur J Clin Pharmacol 31 (1987): 677-83. [PMID: 3556375] | ||||
130 | Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ. | ||||
131 | Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC. | ||||
132 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
133 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
134 | Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL. | ||||
135 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
136 | Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ. | ||||
137 | Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
138 | Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168] | ||||
139 | Helleberg L, Rubin A, Wolen RL, et al "A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent." Br J Clin Pharmacol 1 (1974): 371-4. [PMID: 22454912] | ||||
140 | Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ. | ||||
141 | Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA. | ||||
142 | Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
143 | Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990] | ||||
144 | Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993. | ||||
145 | Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022] | ||||
146 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
147 | Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN. | ||||
148 | Canadian Pharmacists Association. | ||||
149 | Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA. | ||||
150 | Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY. | ||||
151 | Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ. | ||||
152 | Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT. | ||||
153 | Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL. | ||||
154 | Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY. | ||||
155 | Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res. 1988;49(2):245-249. [PMID: 3348533] | ||||